| Trial ID: | L0079 |
| Source ID: | NCT00495365
|
| Associated Drug: |
Epoetin Alfa
|
| Title: |
A Dose Conversion Study of Epoetin Alfa in Subjects With the Anemia of Chronic Kidney Disease.
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Anemia|Chronic Renal Insufficiency
|
| Interventions: |
DRUG: Epoetin alfa
|
| Outcome Measures: |
Primary: The primary objective was to evaluate the proportion of subjects who maintained hemoglobin levels within 10% of entry levels and/or a range of 11-13 g/dL for the 24-week duration of the study. | Secondary: The secondary objective was to evaluate safety in subjects with chronic kidney disease throughout the study
|
| Sponsor/Collaborators: |
Sponsor: Ortho Biotech Products, L.P.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
8
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2003-06
|
| Completion Date: |
2003-09
|
| Results First Posted: |
|
| Last Update Posted: |
2011-05-19
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00495365
|
